ARID1A protein expression in endometriosis-associated ovarian carcinomas

In: Journal of Physics: Conference Series · 2019 · vol. 1246(1) , pp. 012070 · doi:10.1088/1742-6596/1246/1/012070 · W2958425851
article OA: diamond CC0

Abstract

Abstract Epithelial ovarian carcinoma is leading cause of death among gynaecologic malignancies. Somatic mutation of ARID1A gene often observed in endometriosis-associated ovarian carcinoma cases. This mutation causes loss of ARID1A protein expression on tumor-bearing tissues. This study aims to investigate ARID1A protein expression in endometriosis-associated ovarian carcinoma cases in Indonesia. The archive of Formalin-fixed paraffin embedded (FFPE) tissue of 11 endometrial carcinomas (EC), 16 clear cell carcinoma (CCC), and 23 serous carcinomas (SC) from January 1, 2016, to December 31, 2017. The ARID1A expression were analyzed by using Kolmogorov Smirnov and Fisher’s Exact Tests. Majority of patients were older than 50 years (90%). Loss of ARID1A expression in tumor tissue was significantly low in the SC group (8.7%) compared to the EC group (27.3%) and the CCC group (62.5%) (p = 0.021). This study showed that ARID1A expression, was not associated with FIGO stage (p = 0,423), and with histological grade of the cases in EC group (p = 0,544) and SC group (p = 0,395). Loss of ARID1A expression was more frequently found in EC and CCC cases. Loss of ARID1A expression was not associated with FIGO stage and histological grade.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (28)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK